genetically engineered ny-eso-1-specific t lymphocytes
Cell therapyexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2017 (NCT03017131)
Timeline
Indications
Mechanism of action
- Cancer/testis antigen 1Immunity, passive
Cancer/testis antigen 1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- genetically engineered ny-eso-1-specific t lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05549921 | Phase 2 | Jul 8, 2022 | Guangdong Xiangxue Precision Medical Technology Co., Ltd., Sun Yat-Sen University |
| NCT03462316 | Phase 1 | May 21, 2018 | Guangdong Xiangxue Precision Medical Technology Co., Ltd, Sun Yat-Sen University |
| NCT03017131 | Phase 1 | Jun 1, 2017 | National Cancer Institute (NCI), State University of New York, Buffalo |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sun Yat-Sen University | Academic/Hospital | 2 | 2 | 2 | 2018 |
| Guangdong Xiangxue Precision Medical Technology Co., Ltd | For profit | 1 | 0 | 1 | 2018 |
| Guangdong Xiangxue Precision Medical Technology Co., Ltd. | Academic/Hospital | 1 | 0 | 1 | 2022 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2017 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 2017 |
5 organizations
Page 1 / 1